Xiaoling Zeng

Xiaoling Zeng

Auto-generated profile, based on publicly available information

Xiaoling Zeng

Geneplus-Beijing Institute, Beijing, P.R. China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
BSBoyang Sun
Boyang Sun
TQTian Qiu
Tian Qiu
XZXiaoling Zeng
Xiaoling Zeng
JDJian Chun Duan
Jian Chun Duan
HBHua Bai
Hua Bai
ZWZhijie Wang
Zhijie Wang
Next-generation sequencing (NGS) has failed to detect mesenchymal epithelial transition factor gene (MET) polysomy in previous studies. We included three non–small cell lung cancer (NSCLC) cohorts in this retrospective study to establish new criteria for detecting MET polysomy and to explore the clinical relevance of MET polysomy. Cohort 1 included 53 patients whose tissues were available for both FISH and NGS assays. Paired plasma and tissue samples were obtained from 261 patients with NSCLC as cohort 2. Cohort 3 included 46 patients with metastatic NSCLC, who presented with MET copy-number gain assessed by NGS. ROC analysis demonstrated that a cut-off point of 2.3 copies achieved the maximum Youden index in discriminating polysomy from normal copy number. Compared with the FISH test for MET polysomy, the sensitivity, specificity, and agreement of NGS were 90%, 90%, and 96.2%, respectively. Following optimization using maximum somatic allele frequency, the sensitivity and specificity of NGS for defining polysomy using plasma samples according to different circulating tumor DNA mutation frequencies were 42% and 63%. The concordance rate between tissue and plasma samples for detecting polysomy was 85%. Regarding the response to MET inhibitor, the median progression-free survival (PFS) of the MET amplification group was significantly higher than that of the polysomy group. The median PFS was similar between the polysomy and normal groups. Our results indicated that NGS may serve as an alternative method for detecting MET polysomy in NSCLC tissues. Moreover, patients with MET polysomy may not benefit from MET inhibitors.Significance: In this study, we established a methodology to differentiate polysomy from normal copy numbers and amplification using NGS. Moreover, this study suggests that it is critical to discriminate MET polysomy from amplification, for the former may dilute the clinical benefit of MET inhibitors.

1 July 2020 in Lung Cancer
Verified
Journal Article
Closed access
MZMinglei Zhuo
Minglei Zhuo
ZLZhen Liang
Zhen Liang
YYYuting Yi
Yuting Yi
NWNan Wu
Nan Wu
XYXue Yang
Xue Yang
JZJUN ZHAO
JUN ZHAO

4 April 2023
Verified
Other
Open access
BSBoyang Sun
Boyang Sun
TQTian Qiu
Tian Qiu
XZXiaoling Zeng
Xiaoling Zeng
JDJian Chun Duan
Jian Chun Duan
HBHua Bai
Hua Bai
ZWZhijie Wang
Zhijie Wang
One MET-FISH polysomy tumor was classified as negative using the NGS assay.

4 April 2023
Verified
Other
Open access
BSBoyang Sun
Boyang Sun
TQTian Qiu
Tian Qiu
XZXiaoling Zeng
Xiaoling Zeng
JDJian Chun Duan
Jian Chun Duan
HBHua Bai
Hua Bai
ZWZhijie Wang
Zhijie Wang
One MET-FISH polysomy tumor was classified as negative using the NGS assay.

4 April 2023
Verified
Other
Open access
BSBoyang Sun
Boyang Sun
TQTian Qiu
Tian Qiu
XZXiaoling Zeng
Xiaoling Zeng
JDJian Chun Duan
Jian Chun Duan
HBHua Bai
Hua Bai
ZWZhijie Wang
Zhijie Wang
One MET-FISH-negative patient was classified as having MET polysomy by NGS

4 April 2023
Verified
Other
Open access
BSBoyang Sun
Boyang Sun
TQTian Qiu
Tian Qiu
XZXiaoling Zeng
Xiaoling Zeng
JDJian Chun Duan
Jian Chun Duan
HBHua Bai
Hua Bai
ZWZhijie Wang
Zhijie Wang
One MET-FISH polysomy tumor was classified as negative using the NGS assay.